mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Diabetic nephropathy (DN) is among the most lethal complications that occur in type 1 and type 2 diabetics. Podocyte dysfunction is postulated to be a critical event associated with proteinuria and glomerulosclerosis in glomerular diseases including DN. However, molecular mechanisms of podocyte dysfunction in the development of DN are not well understood. Here we have shown that activity of mTOR complex 1 (mTORC1), a kinase that senses nutrient availability, was enhanced in the podocytes of diabetic animals. Further, podocyte-specific mTORC1 activation induced by ablation of an upstream negative regulator (PcKOTsc1) recapitulated many DN features, including podocyte loss, glomerular basement membrane thickening, mesangial expansion, and proteinuria in nondiabetic young and adult mice. Abnormal mTORC1 activation caused mislocalization of slit diaphragm proteins and induced an epithelial-mesenchymal transition-like phenotypic switch with enhanced ER stress in podocytes. Conversely, reduction of ER stress with a chemical chaperone significantly protected against both the podocyte phenotypic switch and podocyte loss in PcKOTsc1 mice. Finally, genetic reduction of podocyte-specific mTORC1 in diabetic animals suppressed the development of DN. These results indicate that mTORC1 activation in podocytes is a critical event in inducing DN and suggest that reduction of podocyte mTORC1 activity is a potential therapeutic strategy to prevent DN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although podocytes have high basal levels of autophagy, high mTORC1 activity is also required for these cells to maintain their function”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ulianich, L., Garbi, C., Treglia, A. S., Punzi, D., Miele, C., Raciti, G. A., Bèguinot, F., Consiglio, E., & Jeso, B. D. (2008) · Journal of Cell Science · doi:10.1242/jcs.017202 · Cited by 114
RetractedTOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Self-citationThe Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Self-citationKestilä, M., Lenkkeri, U., Männikkö, M., Lamerdin, J., McCready, P., Putaala, H., Ruotsalainen, V., Morita, T., Nissinen, M., Herva, R., et al. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80057-x · Cited by 1,866
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber, A., Dahan, K., Gubler, M.-C., Niaudet, P., & Antignac, C. (2000) · Nature Genetics · doi:10.1038/74166 · Cited by 1,444
Research works printed but not linked: 2
- Zhong, Am J Respir Cell Mol Biol.
- Kouraklis, 2006, Oncol Rep., 15, 489
Cited by
Items 101–200 of 544
Renal Allograft Fibrosis: Biology and Therapeutic Targets
Boor, P., & Floege, J. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13180 · Cited by 116
Guo, H., Wu, H., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086978 · Cited by 122
“Knockout of the tsc1 gene (which negatively regulates the mTOR factor) in mice resulted in increased endoplasmic reticulum stress and eventually diabetic nephropathy [29].”
BackgroundPodocytes maintain high basal levels of autophagy independent of mtor signaling
Bork, T., Liang, W., Yamahara, K., Lee, P., Tian, Z., Liu, S., Schell, C., Thedieck, K., Hartleben, B., Patel, K., et al. (2020) · Autophagy · doi:10.1080/15548627.2019.1705007 · Cited by 100
“Mice bearing Tsc1 flox (exons 17 and 18) or Rptor flox alleles (exon 6) have been previously reported [30,79,80].”
BackgroundSelf-citationmTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans
Puelles, V. G., van der Wolde, J. W., Wanner, N., Scheppach, M. W., Cullen‐McEwen, L. A., Bork, T., Lindenmeyer, M. T., Gernhold, L., Wong, M. N., Braun, F., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99271 · Cited by 102
“In contrast, hyperactivity of the mTOR pathway in podocytes leads to pathological changes associated with diabetic nephropathy (19) and crescentic nephritis (20).”
BackgroundSelf-citationLoss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay
Fiorentino, L., Cavalera, M., Menini, S., Marchetti, V., Mavilio, M., Fabrizi, M., Conserva, F., Casagrande, V., Menghini, R., Pontrelli, P., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201475 · Cited by 98
“…including hypoxia or ER stress (Kume et al, 2012; Mizushima & Komatsu, 2011), and plays an important role as a survival factor especially in post-mitotic cells such as podocytes (Fogo, 2011; Godel et al, 2011; Hartleben et al, 2010; He et al, 2010; Inoki et al, 2011; Kume et al, 2010; Nath, 2010).”
Kitada, M., Ogura, Y., Suzuki, T., Sen, S., Lee, S. M., Kanasaki, K., Kume, S., & Koya, D. (2016) · Diabetologia · doi:10.1007/s00125-016-3925-4 · Cited by 97
Self-citationZhao, X., Chen, Y., Tan, X., Zhang, L., Zhang, H., Li, Z., Liu, S., Li, R., Lin, T., Liao, R., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5077 · Cited by 93
“The hyperactivation of mTOR in podocytes is a crucial step in the development of DN [7], but the role of hyperactive mTOR in podocyte autophagy under DM conditions had not been explored.”
BackgroundRheb/mTORC1 Signaling Promotes Kidney Fibroblast Activation and Fibrosis
Jiang, L., Xu, L., Mao, J., Li, J., Fang, L., Zhou, Y., Liu, W., He, W., Zhao, A. Z., Yang, J., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050476 · Cited by 92
Coming full circle in diabetes mellitus: from complications to initiation
Harcourt, B. E., Penfold, S. A., & Forbes, J. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.236 · Cited by 97
Beirowski, B., Wong, K. M., Babetto, E., & Milbrandt, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620761114 · Cited by 86
“Indeed, in some cell types proliferation appears even reduced (51, 52).”
BackgroundPodocyte-targeted therapies — progress and future directions
Meliambro, K. A., He, C., & Campbell, K. N. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00843-z · Cited by 93
“By contrast, activation of mTORC1, one of the main components of the mTOR complex, has been shown to promote podocyte injury and proteinuria in mouse models of DKD 89 and MCD 90 as well as the formation of cellular crescents in mice 91 .”
Margaria, J. P., Campa, C. C., Santis, M. C. D., Hirsch, E., & Franco, I. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109468 · Cited by 90
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
Walters, H. E., & Cox, L. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082325 · Cited by 85
“Experimentally increasing mTORC1 activity in mouse podocytes induces DN phenotypes, podocyte loss, and mis-localization of Nephrin, a cell surface protein that is important in production of the renal filtration barrier [202], while reduced mTORC1 activity prevents DN progression [202].”
BackgroundSalatto, C. T., Miller, R., Cameron, K. O., Cokorinos, E., Reyes, A. R., Ward, J., Calabrese, M. F., Kurumbail, R. G., Rajamohan, F., Kalgutkar, A. S. S., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237925 · Cited by 85
“Glomerular mechanistic target of rapamycin (mTOR) activity is an established driver of podocyte hypertrophy and compromised filtration barrier (Gödel et al., 2011; Inoki et al., 2011; Inoki and Huber, 2012; Eid et al., 2013).”
BackgroundMok, K., Mruk, D. D., & Cheng, C. Y. (2013) · International review of cytology · doi:10.1016/b978-0-12-407704-1.00006-3 · Cited by 90
Podocyte energy metabolism and glomerular diseases
Imasawa, T., & Rossignol, R. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.013 · Cited by 90
Metabolic Flexibility and Its Impact on Health Outcomes
Palmer, B. F., & Clegg, D. J. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.01.012 · Cited by 93
“Increased levels of ketone bodies following SGLT2i exert a kidney protective effect by suppressing mTORC1 signaling in the proximal tubule.(92,93) States of overnutrition lead to hyperactivation of mTORC1, which is strongly associated with structural injury in models of diabetic kidney disease.”
BackgroundKravets, I., & Mallipattu, S. K. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa029 · Cited by 91
“The molecular event responsible for this hypertrophy is activation of mammalian target of rapamycin signaling, a process responsible for cellular development and regeneration [54, 55].”
BackgroundInhibition of insulin/IGF‐1 receptor signaling protects from mitochondria‐mediated kidney failure
Ising, C., Koehler, S., Brähler, S., Merkwirth, C., Höhne, M., Baris, O. R., Hagmann, H., Kann, M., Fabretti, F., Dafinger, C., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404916 · Cited by 87
Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice
Xiao, T., Guan, X., Nie, L., Wang, S., Sun, L., He, T., Huang, Y., Zhang, J., Yang, K., Wang, J., et al. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2090-7 · Cited by 85
“Moreover, recent reports proposed that the activation of mTOR in podocytes is a key link for the development of DN, and a reduction in the activation of mTOR in podocytes can contributed to the delayed progression of DN [33, 34].”
BackgroundSelf-citationTargeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer
Li, H., Lin, J., Wang, X., Yao, G., Wang, L., Zheng, H., Yang, C., Jia, C., Liu, A., & Bai, X. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2036-2 · Cited by 82
“in epithelial, colon cancer, and podocytes [33–35], we found that inhibition of mTORC2 but not mTORC1 pro-”
BackgroundLin, Y., Kuro‐o, M., & Sun, Z. (2013) · Endocrinology · doi:10.1210/en.2013-1053 · Cited by 85
“It was reported that activity of mTOR complex 1, a kinase that senses nutrient availability, was enhanced in the podocytes of diabetic animals (47).”
BackgroundMok, K., Mruk, D. D., Silvestrini, B., & Cheng, C. Y. (2012) · Endocrinology · doi:10.1210/en.2012-1665 · Cited by 80
Huang, C., Lin, M. Z., Cheng, D., Braet, F., Pollock, C. A., & Chen, X. (2016) · Scientific Reports · doi:10.1038/srep23884 · Cited by 81
Targeting mTOR Signaling Can Prevent the Progression of FSGS
Zschiedrich, S., Bork, T., Liang, W., Wanner, N., Eulenbruch, K., Munder, S., Hartleben, B., Kretz, O., Gerber, S., Simons, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016050519 · Cited by 76
Self-citationSalemkour, Y., Yildiz, D., Dionet, L., Hart, D. C. ‘., Verheijden, K. A. T., Saito, R., Mahtal, N., Delbet, J., Letavernier, E., Rabant, M., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000212 · Cited by 76
“18 – 20 The molecular mechanisms underlying impaired podocyte autophagy during DKD remain elusive.”
BackgroundTwenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy
Johnson, S. A., & Spurney, R. F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00266.2015 · Cited by 79
From podocyte biology to novel cures for glomerular disease
Torban, E., Braun, F., Wanner, N., Takano, T., Goodyer, P., Lennon, R., Ronco, P. M., Cybulsky, A. V., & Huber, T. B. (2019) · Kidney International · doi:10.1016/j.kint.2019.05.015 · Cited by 76
Self-citationCell Apoptosis and Autophagy in Renal Fibrosis
Zhao, X., Livingston, M. J., Liang, X., & Dong, Z. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_28 · Cited by 78
Packer, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13961 · Cited by 83
Targeting immune cell metabolism in kidney diseases
Basso, P. J., Andrade‐Oliveira, V., & Câmara, N. O. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00413-7 · Cited by 80
Fasting and rapamycin: diabetes versus benevolent glucose intolerance
Blagosklonny, M. V. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1822-8 · Cited by 74
Liu, T., Yang, L., Mao, H., Ma, F., Wang, Y., & Zhan, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.772386 · Cited by 80
Hu, T., Yue, J., Tang, Q., Cheng, K., Chen, F., Peng, M., Zhou, Q., & Wang, M. (2022) · Food & Function · doi:10.1039/d1fo03958j · Cited by 80
Podocyte EGFR Inhibits Autophagy Through Upregulation of Rubicon in Type 2 Diabetic Nephropathy
Li, Y., Pan, Y., Cao, S., Sasaki, K., Wang, Y., Niu, A., Fan, X., Wang, S., Zhang, M., & Harris, R. C. (2020) · Diabetes · doi:10.2337/db20-0660 · Cited by 75
Podocyte loss involves MDM2 ‐driven mitotic catastrophe
Mulay, S. R., Thomasová, D., Ryu, M., Kulkarni, O. P., Migliorini, A., Bruns, H., Gröbmayr, R., Lazzeri, E., Lasagni, L., Liapis, H., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4193 · Cited by 79
“It is likely that podocyte MDM2 has a similar role to mTOR, eg in diabetic glomerulosclerosis [62,63].”
BackgroundmTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes
Eid, S., Boutary, S. S., Braysh, K., Sabra, R., Massaad, C., Hamdy, A., Rashid, A., Moodad, S., Block, K. L., Gorin, Y. C., et al. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6562 · Cited by 74
Podocytes, Signaling Pathways, and Vascular Factors in Diabetic Kidney Disease
Brosius, F. C., & Coward, R. J. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.011 · Cited by 74
“Assessing Akt2 in the setting of DKDwill be critical, especially in light of the evidence that mTOR in the podocyte is activated in a detrimental way in diabetes and that treatment with an mTOR inhibitor may be beneficial.(39) These recent findings indicate that such treatment could also be detrimental because mTORC1…”
Fogo, A. B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57935 · Cited by 74
Autophagy and its therapeutic potential in diabetic nephropathy
Han, Y.-P., Liu, L., Yan, J.-L., Chen, M., Meng, X., Zhou, X., & Qian, L.-B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1139444 · Cited by 74
“overactivation of the mTOR pathway is extremely detrimental to the development of DN (101, 102).”
BackgroundmTOR Signaling in Autophagy Regulation in the Kidney
Inoki, K. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.11.002 · Cited by 69
Self-citationBera, A., Das, F., Ghosh‐Choudhury, N., Mariappan, M. M., Kasinath, B. S., & Choudhury, G. G. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00081.2017 · Cited by 74
Endoplasmic reticulum stress and kidney dysfunction
Gallazzini, M., & Pallet, N. (2018) · Biology of the Cell · doi:10.1111/boc.201800019 · Cited by 74
“, 2017], diabetic kidney disease [Godel et al., 2011; Inoki et al., 2011; Zhuang and Forbes, 2014], hypertension-associated (and aldosterone mediated) kidney disease [Yuan et al.”
BackgroundLi, C., Guan, X.-M., Wang, R.-Y., Xie, Y.-S., Zhou, H., Ni, W.-J., & Tang, L.-Q. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117277 · Cited by 70
Rozen‐Zvi, B., Hayashida, T., Hubchak, S. C., Hanna, C., Platanias, L. C., & Schnaper, H. W. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00215.2013 · Cited by 70
Proteinuria after kidney transplantation
Ponticelli, C. E., & Graziani, G. (2012) · Transplant International · doi:10.1111/j.1432-2277.2012.01500.x · Cited by 69
“Moreover, studies in mice reported that an abnormal activation of mTORC1 in podocytes induces diabetic nephropathy, suggesting that reduction of podocyte mTORC1 activity is a potential therapeutic strategy to prevent diabetic nephropathy [43].”
BackgroundCharacterization of a vacuolar zinc transporter OZT1 in rice (Oryza sativa L.)
Lan, H., Wang, Z., Wang, Q.-H., Wang, M., Bao, Y., Huang, J., & Zhang, H. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2162-2 · Cited by 73
“Besides, research on PtMTP1 showed that it contained a Leu zipper motif [22] in the C-terminal from residues Leu-293 to Leu-314, which characterized as a repeat pattern of Leu residues at every seventh position Fig.”
Cellular and molecular mechanisms of diabetic glomerulopathy
Gnudi, L. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs121 · Cited by 76
“Recently, podocyte-specific activation of mTOR has resulted in a DN-like phenotype, while the genetic reduction of mTORC1 activity significantly prevented renal disease in experimental animal models of diabetes [46, 47].”
BackgroundKim, Y., Lee, H., Manson, S. R., Lindahl, M., Evans, B. S., Miner, J. H., Urano, F., & Chen, Y. M. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014100986 · Cited by 68
The complicated role of mitochondria in the podocyte
Gujarati, N. A., Vasquez, J. M., Bogenhagen, D. F., & Mallipattu, S. K. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00393.2020 · Cited by 73
Therapeutic potential of pro-resolving mediators in diabetic kidney disease
Vartak, T., Godson, C., & Brennan, E. P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113965 · Cited by 72
Autophagy: Emerging Therapeutic Target for Diabetic Nephropathy
Kume, S., Yamahara, K., Yasuda, M., Maegawa, H., & Koya, D. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.11.003 · Cited by 68
Martín‐Pérez, R., Palacios, C., Yerbes, R., Cano-González, A., Iglesias‐Serret, D., Gil, J., Reginato, M. J., & López‐Rivas, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1747 · Cited by 76
“Recent studies have reported that chronic activation of mTORC1 results in an increase in PERK activity and sensitivity to endoplasmic reticulum stress, although the molecular mechanism leading to cell death was not elucidated (11, 12, 38, 39).”
mTOR Inhibition and Kidney Diseases
Ma, M. K. M., Yung, S., & Chan, T. M. (2018) · Transplantation · doi:10.1097/tp.0000000000001729 · Cited by 70
Currenti, W., Godos, J., Castellano, S., Mogavero, M. P., Ferri, R., Caraci, F., Grosso, G., & Galvano, F. (2020) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2020.1866504 · Cited by 70
“Ramadan can be considered as a form of TRF in which individuals abstain from all food and drink from sunrise to sunset for approximately 30 days (Ismail et al. 2019).”
BackgroundEndoplasmic Reticulum Stress in the Diabetic Kidney, the Good, the Bad and the Ugly
Cunard, R. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040715 · Cited by 68
“mTORC1 activation in podocytes promotes the development of diabetic nephropathy [138,139] and it is associated with ER stress.”
BackgroundTsai, S.-Y., Rodriguez, A. A., Dastidar, S. G., Del Greco, E., Carr, K. L., Sitzmann, J. M., Academia, E. C., Viray, C. M., Martinez, L. L., Kaplowitz, B. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.029 · Cited by 63
“Reduced mTORC1 activity has been reported to prevent development of T2D and protect against diabetic nephropathy in both type I and type II diabetic mouse models (Godel et al., 2011; Inoki et al., 2011; Polak et al., 2008; Um et al., 2004; Yang et al., 2007).”
BackgroundSirt6 deficiency results in progression of glomerular injury in the kidney
Huang, W., Liu, H., Zhu, S., Woodson, M., Liu, R., Tilton, R. G., Miller, J. D., & Zhang, W. (2017) · Aging · doi:10.18632/aging.101214 · Cited by 71
Role of mTOR Inhibitors in Kidney Disease
Kajiwara, M., & Masuda, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060975 · Cited by 66
“Further precise investigation into the effects of mTOR inhibitors on polycystic kidney disease is needed to enable their clinical application [32].”
BackgroundCompensatory renal hypertrophy following nephrectomy: When and how?
Rojas‐Canales, D. M., Li, J. Y. Z., Makuei, L., & Gleadle, J. (2019) · Nephrology · doi:10.1111/nep.13578 · Cited by 64
Insulin signaling: implications for podocyte biology in diabetic kidney disease
Coward, R. J., & Fornoni, A. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000078 · Cited by 67
“In particular, the AMP-activated protein kinase (AMPK) [61] and the mTOR pathways [62,63] are key direct modulators of podocyte function that can be affected by intracellular glucose.”
BackgroundSun, L., Liu, X.-C., Chen, X., Guan, G., & Liu, G. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.159 · Cited by 63
Diabetes-accelerated experimental osteoarthritis is prevented by autophagy activation
Ribeiro, M. P., de Figueroa, P. L., Nogueira-Recalde, U., Centeno, A., Mendes, A. F., Blanco, F. J., & Caramés, B. (2016) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2016.06.019 · Cited by 63
Yoshida, S., Wei, X., Zhang, G., O'Connor, C. L., Torres, M., Zhou, Z., Lin, L. L., Menon, R., Xu, X., Zheng, W., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143988 · Cited by 67
“viously described standard methods (19, 58).”
MethodSelf-citationBarutta, F., Grimaldi, S., Franco, I., Bellini, S., Gambino, R., Pinach, S., Corbelli, A., Bruno, G., Rastaldi, M. P., Aveta, T., et al. (2014) · Kidney International · doi:10.1038/ki.2014.165 · Cited by 62
Self-citationZhuang, A., & Forbes, J. M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0517 · Cited by 64
mTOR controls kidney epithelia in health and disease
Grahammer, F., Wanner, N., & Huber, T. B. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft491 · Cited by 61
“However, podocyte dysfunction was directly associated with mTORC1-induced endoplasmic reticulum (ER) stress and the reduction of ER stress by using the chemical chaperon (4-phenylbutyrate) abolished podocyte loss in podocyte-specific TSC1 knock-out (KO) mice [28].”
BackgroundResultInfluentialSelf-citationRole of Nutrient-Sensing Signals in the Pathogenesis of Diabetic Nephropathy
Kume, S., Koya, D., Uzu, T., & Maegawa, H. (2014) · BioMed Research International · doi:10.1155/2014/315494 · Cited by 60
“Two recent studies using heterozygous-raptor knockout mice revealed that hyperactivation of the mTORC1 signal is strongly associated with the progression of podocyte injury and proteinuria in diabetic animal models [27, 28].”
BackgroundCastro, W., Chelbi, S. T., Niogret, C., Ramón-Barros, C., Welten, S. P. M., Osterheld, K., Wang, H., Rota, G., Morgado, L., Vivier, É., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0144-9 · Cited by 65
Chen, Y., Liu, Q., Shan, Z., Mi, W., Zhao, Y., Li, M., Wang, B., Zheng, X., & Feng, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01477 · Cited by 64
“Furthermore, the exceeding activation of mTOR has been reported in podocytes in DN patients, which play a key role in the progression of DN (Gödel et al., 2011; Inoki et al., 2011).”
BackgroundCao, H., Luo, J., Zhang, Y., Mao, X., Wen, P., Ding, H., Xu, J., Sun, Q., He, W., Dai, C., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.03.035 · Cited by 65
Crosstalk between glomeruli and tubules
Fogo, A. B., & Harris, R. C. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00907-0 · Cited by 67
“Of note, mTORC1 increases have been implicated in podocyte injury in diabetes 99,100 , but glomerular cell transcriptional changes were not described in the above human biopsy study 98 .”
Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy
Zhang, Y., Ma, K. L., Liu, J., Wu, Y., Hu, Z. B., Liu, L., Lü, J., Zhang, X., & Liu, B. C. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0753-9 · Cited by 61
“Podocyte dysfunction is a critical event associated with proteinuria and glomerulosclerosis in DN [23].”
BackgroundEffects of High Glucose and Lipotoxicity on Diabetic Podocytes
Nakamichi, R., Hayashi, K., & Itoh, H. (2021) · Nutrients · doi:10.3390/nu13010241 · Cited by 64
“have reported that abnormal mTORC1 activation caused mislocalization of slit diaphragm proteins and induced endoplasmic reticulum (ER) stress in podocytes, which suggest mTORC1 activation in podocytes is a critical event in inducing DN [22].”
BackgroundThe mTOR promotes oxidative stress-induced apoptosis of mesangial cells in diabetic nephropathy
Lü, Q., Zhou, Y., Hao, M., Li, C., Wang, J., Shu, F., Du, L., Zhu, X., Zhang, Q., & Yin, X. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.12.012 · Cited by 61
Self-citationResearch Progress on the Pathological Mechanisms of Podocytes in Diabetic Nephropathy
Zhang, L., Wen, Z., Han, L., Zheng, Y., Wei, Y., Wang, X., Wang, Q., Fang, X., Zhao, L., & Tong, X. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7504798 · Cited by 72
“MTORC1 was highly activated after knockout of a podocyte-specific upstream inhibitor of mTOR gene tuberous sclerosis complex 1 (TSC1), which inhibited autophagosomes by activating UNC-51-like kinase (ULK1) activity, resulting in podocyte damage [28, 32, 33].”
BackgroundYang, L., Liang, B., Li, J., Zhang, X., Chen, H., Sun, J. M., & Zhang, Z. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110206 · Cited by 64
Klotho’s impact on diabetic nephropathy and its emerging connection to diabetic retinopathy
Tang, A., Zhang, Y., Wu, L., Lin, Y., Lv, L., Zhao, L., Xu, B., Huang, Y., & Li, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1180169 · Cited by 62
Ruby, Gifford, C. C., Pandey, R. P., Raj, V., Sabbisetti, V. S., & Ajay, A. K. (2023) · Cells · doi:10.3390/cells12030412 · Cited by 62
“Studies investigating the activation of mTOR signaling find that short-term treatment of mTOR activation protects podocytes in diabetes mellitus, but long-term activation can lead to proteinuria and progressive glomerulosclerosis [89,98].”
BackgroundAutophagy in Glomerular Health and Disease
Hartleben, B., Wanner, N., & Huber, T. B. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.11.007 · Cited by 60
Self-citationEpigenetics: a new way to look at kidney diseases
Beckerman, P., Ko, Y.-A., & Suszták, K. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu026 · Cited by 59
“Previously, characterization and localization of these important regulatory elements has proved to be difficult [8, 9].”
BackgroundGuzman, J., Jauregui, A. N., Merscher, S., Maiguel, D. A., Muresan, C., Mitrofanova, A. V., Díez-Sampedro, A., Szust, J., Yoo, T., Villarreal, R., et al. (2013) · Diabetes · doi:10.2337/db13-0752 · Cited by 61
“In particular, the AMP-activated protein kinase (AMPK) (17) and the mammalian target of rapamycin (mTOR) pathways (18,19) are key direct modulators of podocyte function that can be affected by intracellular glucose.”
InfluentialSelf-citationMammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications
Lieberthal, W., & Levine, J. S. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00015.2012 · Cited by 57
“In the case of DN, renal enlargement and glomerular hypertrophy also precede nephron loss and occur in association with an increased GFR (36, 66, 73).”
BackgroundInfluentialLin, Y., Lee, Y., Hsu, Y., Chen, Y.-J., Lin, Y., Cheng, F., & Chiu, H. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0256 · Cited by 62
Bissler, J. J., Budde, K., Sauter, M., Franz, D. N., Zonnenberg, B. A., Frost, M., Белоусова, Е. Д., Berkowitz, N. C., Ridolfi, A., & Kingswood, J. C. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy132 · Cited by 58
“Furthermore, the timing and effects of mTOR inhibition appear to be important, with early inhibition with rapamycin preventing renal injury caused by mTORC1 activation in podocytes [26, 39].”
BackgroundControversies in Podocyte Loss: Death or Detachment?
Yin, L., Lu, Y., He, C., & Chen, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.771931 · Cited by 57
“On the one hand, podocyte effacement reduced the buttressing force of podocytes and the compressive force of the GBM, subsequently drastically increasing capillary pressure and local fluid flow at the barrier due to the decreased filtration area, thus leading to loss of podocytes through detachment because of enhanced…”
BackgroundInfluentialRoles of mTOR in Diabetic Kidney Disease
Yasuda‒Yamahara, M., Kume, S., & Maegawa, H. (2021) · Antioxidants · doi:10.3390/antiox10020321 · Cited by 60
“It has also been reported that podocyte-specific mTORC1 hyperactivity odel mice with podocytespecific deletion of tuberous sclerosis complex 1, a protein that suppresses mTORC1, show podocyte damage, proteinuria, and an increased mesangial area similar to the glomerular lesions caused by DKD [27].”
BackgroundInfluentialRenal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis
Mao, Z., Tan, Y. C. R. S., Tao, J., Li, L., Wang, H., Yu, F., Perl, A., & Zhao, M. (2022) · Rheumatology · doi:10.1093/rheumatology/keac037 · Cited by 61
New targets for treatment of diabetic nephropathy: what we have learned from animal models
Brosius, F. C., & Alpers, C. E. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32835b3766 · Cited by 56
Investigations of Glucocorticoid Action in GN
Kuppe, C., van Roeyen, C. R. C., Leuchtle, K., Kabgani, N., Vogt, M., van Zandvoort, M. A. M. J., Smeets, B., Floege, J., Gröne, H., & Moeller, M. J. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016010060 · Cited by 57
Fan, W., Han, D. H., Sun, Z., Ma, S., Gao, L., Chen, J., Li, X., Li, X., Fan, M., Li, C., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.05.001 · Cited by 59
“Likewise, Inoki and co-workers proved that mTORC1 activation in podocytes is crucial in the development of diabetic nephropathy in mice, and genetic reduction of podocyte-specific mTORC1 in diabetic mice palliated the progression of diabetic nephropathy [35].”
BackgroundAutophagy and mitophagy: physiological implications in kidney inflammation and diseases
Bhatia, D., & Choi, M. E. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00012.2023 · Cited by 57
Repair Problems in Podocytes: Wnt, Notch, and Glomerulosclerosis
Kato, H., & Suszták, K. (2012) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.06.006 · Cited by 54
“As podocytes are unable to divide, it appears that they enlarge in response to podocyte injury, potentially via regulation of the mTOR pathway (6, 8, 9).”
BackgroundLi, Z., Xu, J., Xu, P., Liu, S., & Yang, Z. R. (2013) · Cell Proliferation · doi:10.1111/cpr.12010 · Cited by 56
Elevated urinary CRELD2 is associated with endoplasmic reticulum stress–mediated kidney disease
Kim, Y., Park, S.-J., Manson, S. R., Molina, C. A. F., Kidd, K. O., Thiessen‐Philbrook, H., Perry, R., Liapis, H., Kmoch, S., Parikh, C. R., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92896 · Cited by 53
“Of note, CRELD2 induction was observed in the urine of patients 4, 5, 9, 14, and 15 whose estimated glomerular filtration rates (eGFR) were 111.19, 66.34, 102.9, 75.79, and 66.4 ml/min, respectively (Figure 6, C and D, and Table 2).”
BackgroundInfluentialSun, H., Tian, J., Xian, W., Xie, T., & Yang, X. (2015) · Inflammation · doi:10.1007/s10753-015-0151-z · Cited by 57
Su, W., Mruk, D. D., & Cheng, C. Y. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.758084 · Cited by 54
“Furthermore, these findings in the testis is also in agreement with recent studies in other epithelia which have illustrated the involvement of mTORC1 pathway in barrier function regulation and F-actin organization, such as the TJ-barrier in kidney glomerulus and in mouse bladder, except that the effector molecule(s)…”
ResultProgress in Pathogenesis of Proteinuria
Zhang, A., & Huang, S. (2012) · International Journal of Nephrology · doi:10.1155/2012/314251 · Cited by 58
“Podocyte- specific mTORC1 activation in diabetic mice recapitulated many diabetic nephropathy features, including podocyte loss, GBM thickening, mesangial expansion, and proteinuria in addition to podocyte loss [127].”
BackgroundThe Evolving Importance of Insulin Signaling in Podocyte Health and Disease
Lay, A. C., & Coward, R. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00693 · Cited by 54
“In podocytes, signaling via the IR has been shown to influence mTOR activity (22) and, importantly, while regulated mTOR activity is essential for podocyte function, podocyte-specific over-activation of mTORC1 induces podocyte injury and plays an important role in DKD development (42, 43).”
BackgroundHuang, C., Bruggeman, L. A., Hydo, L. M., & Miller, R. T. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.03.011 · Cited by 65
“PLD is a primary enzyme in cell signaling to produce phosphatidic acid (PA) which is a critical activator of mammalian target of rapamycin (mTOR) signaling (19–21), a process linked to increase cell mass associated with glomerular hypertrophy (22, 23).”
Background
Metadata
- Authors
- Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., Kwiatkowski, D. J., Rastaldi, M. P., Huber, T. B., Kretzler, M., Holzman, L. B., Wiggins, R. C., & Guan, K.-L.
- Affiliations
- University of Michigan (US)
- Life Sciences Institute (SG)
- University of Basel (CH)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- University of California San Diego (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2181-2196
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3104745
- OpenAlex
- W2033798110
- Cited by
- 538
- References
- 77
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 23 · 2023: 36 · 2022: 33 · 2021: 22 · 2020: 48 · 2019: 43 · 2018: 39 · 2017: 39 · 2016: 39 · 2015: 35 · 2014: 44 · 2013: 45 · 2012: 36
- FWCI
- 35.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- edoc (University of Basel)
- Funders
- National Institutes of Health (5r01dk083491-09, DK083491)
- National Cancer Institute (R01CA108941)
- National Institute of General Medical Sciences (R01GM051586, GM051586)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK083491, DK-083491, R01DK124709)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Oncology › Renal and related cancers
- Keywords
- diabetic nephropathy, mTORC1, podocytes, podocyte loss, proteinuria, glomerulosclerosis, endoplasmic reticulum stress, epithelial-mesenchymal transition, slit diaphragm proteins, TSC1, chemical chaperones, mesangial expansion, glomerular basement membrane thickening
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Regulatory-Associated Protein of mTOR, Tuberous Sclerosis Complex 1 Protein, Animals, Carrier Proteins, Cell Differentiation, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Disease Models, Animal, Endoplasmic Reticulum, Enzyme Activation, Glomerular Mesangium, Male, Membrane Proteins, Mice, Inbred C57BL, Mice, Mutant Strains, Phosphorylation, Protein Processing, Post-Translational, Proteins, Mice, Knockout, Ribosomal Protein S6 Kinases, Sirolimus, Tumor Suppressor Proteins, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Podocytes, Glomerular Basement Membrane, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.